Priority Medicines (PRIME) is a voluntary scheme operated by the European Medicines Agency (EMA) to support the development of medicines that address unmet medical needs in the European Union. Launched in March 2016, it provides early and enhanced interaction between developers and EMA with the aim of optimising evidence generation and facilitating use of accelerated assessment at the time of marketing authorisation.
